EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Genomic Biomarkers for First-Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma: A Narrative Review

Anushareddy Muddasani iD, Ahmed Abdelnoor, Ashish Manne iD

Cancers · 21.05.2026 · 18 (10) · 1664

DOI: 10.3390/cancers18101664 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 21.05.2026. Verfasst von Anushareddy Muddasani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic pancreatic ductal adenocarcinoma (PDAC) is typically treated with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) or gemcitabine plus nab-paclitaxel (GnP), but the choice between regimens remains largely empirical. This narrative review summarizes biomarkers with potential to inform first-line selection in metastatic PDAC, emphasizing genomic and transcriptomic correlates of differential benefit. Recent head-to-head trials, particularly Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01) and GENERATE (Japan Clinical Oncology Group [JCOG] 1611), indicate that modified FOLFIRINOX (mFOLFIRINOX) is not uniformly superior to GnP, strengthening the rationale for biomarker-guided selection. The strongest evidence favoring platinum-based/FOLFIRINOX strategies involves homologous recombination repair deficiency (HRD), especially alterations in germline breast cancer gene 1/2 (BRCA1/2) or partner and localizer of BRCA2 (PALB2), as well as broader genomic scar signatures. Transcriptomic subtype and GATA-binding protein 6 (GATA6) expression are promising but remain unsettled because retrospective data favor classical/GATA6-high disease for FOLFIRINOX, whereas PASS-01 suggested better outcomes with GnP in classical tumors. Candidate biomarkers favoring GnP include high human equilibrative nucleoside transporter 1 (hENT1), low class III β-tubulin (TUBB3) expression, and exploratory phosphatidylinositol 3-kinase (PI3K)/KIT/NOTCH pathway mutation signals. Comprehensive molecular profiling also identifies actionable alterations that may redirect patients to targeted therapy or clinical trials rather than standard chemotherapy alone. Importantly, no biomarker has yet been prospectively validated in a biomarker-stratified randomized trial with regimen selection as the primary endpoint; all biomarker-regimen associations described in this review should therefore be considered hypothesis-generating rather than practice-defining. Nevertheless, the convergence of genomic, transcriptomic, and organoid-based approaches makes biologically informed first-line selection increasingly feasible in metastatic PDAC.

Schlagwörter

Stichwörter der Autor:innen

FOLFIRINOXbiomarker-guided therapygemcitabine plus nab-paclitaxelhomologous recombination deficiencymetastatic pancreatic cancerpancreatic ductal adenocarcinomaprecision oncologypredictive biomarkerstranscriptomic subtypes

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
  • Department of Internal Medicine, Zagazig University, Zazazig 44519, Egypt.
  • Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.

ORCID-Profile: Anushareddy Muddasani, Ashish Manne

Zitieren

APA

Muddasani, A., Abdelnoor, A., & Manne, A. (2026). Genomic Biomarkers for First-Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma: A Narrative Review. Cancers, 18(10), 1664. https://doi.org/10.3390/cancers18101664

Vancouver

Muddasani A, Abdelnoor A, Manne A. Genomic Biomarkers for First-Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma: A Narrative Review. Cancers. 2026;18(10):1664. doi:10.3390/cancers18101664

BibTeX
@article{Muddasani2026,
  author = {Muddasani, Anushareddy and Abdelnoor, Ahmed and Manne, Ashish},
  title = {Genomic Biomarkers for First-Line Treatment Selection in Metastatic Pancreatic Ductal Adenocarcinoma: A Narrative Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1664},
  doi = {10.3390/cancers18101664}
}
Kostenlos starten →